Vapaliximab is a chimeric monoclonal antibody[1] and an experimental immunosuppressive drug.[citation needed] Development was discontinued by 2012.[2]

References

  1. ^ WHO Drug Information
  2. ^ "Vapaliximab - AdisInsight". adisinsight.springer.com. Retrieved 2 January 2019.


Allikas: https://en.wikipedia.org/wiki/Vapaliximab
No tags for this post.